ArticleScientific reports2025
Metabolic profiling and antibacterial activity of secondary metabolites extracted from the endophytic bacteria of Combretum erythrophyllum.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Octadecyl 3-(3, 5-di-tert-butyl-4-hydroxyphenyl) propanoate nanosponges: enhanced antibacterial and antibiofilm activity against multidrug-resistantFrontiers in cellular and infection microbiology · 2026Article
- A comprehensive review on bacterial endophytic secondary metabolites: a road map from crude extract to lead molecule production.Frontiers in pharmacology · 2026Review
- Real-time simultaneous monitoring of multiple analytes in bacterial cultures.Applied and environmental microbiology · 2025Article
- Integrated analysis of 16 S endophytic bacteria and non-targeted metabolomics reveals the drought response mechanisms of Portulaca Oleracea L.BMC plant biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Antibiotic resistance continues to pose a significant global challenge associated with increased rates of illness and death. The emergence of multidrug resistance patterns in pathogenic bacteria poses a challenge in their treatment, rendering them unmanageable with traditional antibiotics in the foreseeable future. Thus, prioritising innovative pharmaceuticals for therapy and exploring alternate approaches to combat antimicrobial resistance is of utmost importance. Endophytic bacteria derived from medicinal plants are reservoirs of active therapeutic compounds, offering a promising alternative for discovering novel and therapeutically bioactive compounds. This work involved the isolation and identification of four endophytic bacteria from Combretum erythrophyllum. The antibacterial activity and metabolic profiling of the secondary metabolite extract were assessed via the microdilution technique and gas chromatography data analysis, respectively. The assessed extract showed wide-ranging effectiveness against Gram-positive and Gram-negative bacteria, with a particular preference for Klebsiella aerogenes (ATCC 27853) at a minimum inhibitory concentration of 125 µg/mL. The analysed secondary metabolites revealed phytochemicals, namely terpenoids, ketones, phytosterols, phenols, alkanes, and fatty acid methyl esters (FAME) as the bioactive constituents. In conclusion, this study underscores the importance of the endophytic bacteria of C. erythrophyllum as a potential source of active natural bioactive compounds for antibiotic therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.